UA73292C2 - Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins - Google Patents

Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins Download PDF

Info

Publication number: UA73292C2
Authority: UA; Ukraine
Prior art keywords: patients; atorvastatin; study; cholesterol; group
Prior art date: 1998-09-30

Application number

UA2001042933A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-30

Filing date

1999-08-07

Publication date

2005-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA73292(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-08-07 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2005-07-15 Publication of UA73292C2 publication Critical patent/UA73292C2/uk

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Surgical Instruments (AREA)
Media Introduction/Drainage Providing Device (AREA)

UA2001042933A 1998-09-30 1999-08-07 Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins UA73292C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10245798P	1998-09-30	1998-09-30
PCT/US1999/015385 WO2000018395A1 (en)	1998-09-30	1999-07-08	Method for preventing or delaying catheter-based revascularization

Publications (1)

Publication Number	Publication Date
UA73292C2 true UA73292C2 (en)	2005-07-15

Family

ID=22289955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001042933A UA73292C2 (en)	1998-09-30	1999-08-07	Method for prevention or delay of need for catheter-based revascularization in patients suffering from coronary artery disease via using statins

Country Status (34)

Country	Link
US (1)	US20080119561A1 (de)
EP (1)	EP1117392B1 (de)
JP (1)	JP2002525321A (de)
KR (1)	KR20010079955A (de)
CN (1)	CN1197565C (de)
AP (1)	AP1708A (de)
AT (1)	ATE260100T1 (de)
AU (1)	AU768474B2 (de)
BG (1)	BG105471A (de)
BR (1)	BR9914098A (de)
CA (1)	CA2343299C (de)
CZ (1)	CZ20011035A3 (de)
DE (1)	DE69915084T2 (de)
DK (1)	DK1117392T3 (de)
EA (1)	EA007427B1 (de)
EE (1)	EE200100199A (de)
ES (1)	ES2214872T3 (de)
HR (1)	HRP20010236A2 (de)
HU (1)	HUP0103648A3 (de)
ID (1)	ID30255A (de)
IL (2)	IL141953A0 (de)
IS (1)	IS5889A (de)
NO (1)	NO20011615L (de)
NZ (1)	NZ510500A (de)
OA (1)	OA11787A (de)
PL (1)	PL346980A1 (de)
PT (1)	PT1117392E (de)
SI (1)	SI1117392T1 (de)
SK (1)	SK4122001A3 (de)
TR (1)	TR200100901T2 (de)
UA (1)	UA73292C2 (de)
WO (1)	WO2000018395A1 (de)
YU (1)	YU23901A (de)
ZA (1)	ZA200102230B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1216038T3 (da)	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU2001256278A1 (en) *	2000-04-18	2001-10-30	Bayer Aktiengesellschaft	Use of cse inhibitors for treating heart failure
CA2414783A1 (en) *	2000-07-14	2002-01-24	Warner-Lambert Company	Treatment of eating disorders using carboxyalkylethers
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko)	2001-01-26	2007-12-24	쉐링 코포레이션	치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (de)	2001-09-21	2006-11-22	Schering Corporation	Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504916A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2004081002A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de)	2003-03-07	2009-02-05	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5157025A (en) *	1991-04-01	1992-10-20	E. R. Squibb & Sons, Inc.	Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
WO1995013063A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5957916A (en) *	1994-05-25	1999-09-28	The Trustees Of Columbia University In The City Of New York	Myocardial revascularization through the endocardial surface using a laser
US5545628A (en) *	1995-01-10	1996-08-13	Galephar P.R. Inc.	Pharmaceutical composition containing fenofibrate
US5648387A (en) *	1995-03-24	1997-07-15	Warner-Lambert Company	Carboxyalkylethers, formulations, and treatment of vascular diseases
CZ127198A3 (cs) *	1995-11-02	1998-12-16	Warner-Lambert Company	Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
SE506272C2 (sv) *	1996-03-18	1997-11-24	Paul Edholm	Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) *	1996-03-28	1996-07-23	Tel Aviv Medical Center Resear	Drug for hyperlipoproteinemia
AU4228997A (en) *	1996-07-09	1998-02-02	Merck & Co., Inc.	Method for treating homozygous familial hypercholesterolemia
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) *	1997-08-26	2001-01-30	Merck & Co., Inc.	Cholesterol-lowering therapy
NZ503982A (en) *	1997-12-12	2002-03-28	Warner Lambert Co	Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

1999
- 1999-07-08 CZ CZ20011035A patent/CZ20011035A3/cs unknown
- 1999-07-08 PL PL99346980A patent/PL346980A1/xx not_active Application Discontinuation
- 1999-07-08 KR KR1020017004021A patent/KR20010079955A/ko not_active Ceased
- 1999-07-08 CA CA002343299A patent/CA2343299C/en not_active Expired - Fee Related
- 1999-07-08 IL IL14195399A patent/IL141953A0/xx active IP Right Grant
- 1999-07-08 HR HR20010236A patent/HRP20010236A2/hr not_active Application Discontinuation
- 1999-07-08 WO PCT/US1999/015385 patent/WO2000018395A1/en not_active Ceased
- 1999-07-08 TR TR2001/00901T patent/TR200100901T2/xx unknown
- 1999-07-08 EP EP99933763A patent/EP1117392B1/de not_active Revoked
- 1999-07-08 JP JP2000571914A patent/JP2002525321A/ja active Pending
- 1999-07-08 SI SI9930535T patent/SI1117392T1/xx unknown
- 1999-07-08 HU HU0103648A patent/HUP0103648A3/hu unknown
- 1999-07-08 OA OA1200100080A patent/OA11787A/en unknown
- 1999-07-08 NZ NZ510500A patent/NZ510500A/xx unknown
- 1999-07-08 ES ES99933763T patent/ES2214872T3/es not_active Expired - Lifetime
- 1999-07-08 ID IDW20010902A patent/ID30255A/id unknown
- 1999-07-08 BR BR9914098-5A patent/BR9914098A/pt not_active Application Discontinuation
- 1999-07-08 CN CNB998116297A patent/CN1197565C/zh not_active Expired - Fee Related
- 1999-07-08 EA EA200100370A patent/EA007427B1/ru not_active IP Right Cessation
- 1999-07-08 AU AU49750/99A patent/AU768474B2/en not_active Ceased
- 1999-07-08 AT AT99933763T patent/ATE260100T1/de not_active IP Right Cessation
- 1999-07-08 AP APAP/P/2001/002112A patent/AP1708A/en active
- 1999-07-08 PT PT99933763T patent/PT1117392E/pt unknown
- 1999-07-08 EE EEP200100199A patent/EE200100199A/xx unknown
- 1999-07-08 YU YU23901A patent/YU23901A/sh unknown
- 1999-07-08 SK SK412-2001A patent/SK4122001A3/sk unknown
- 1999-07-08 DE DE69915084T patent/DE69915084T2/de not_active Revoked
- 1999-07-08 DK DK99933763T patent/DK1117392T3/da active
- 1999-08-07 UA UA2001042933A patent/UA73292C2/uk unknown
2001
- 2001-03-12 IL IL141953A patent/IL141953A/en not_active IP Right Cessation
- 2001-03-14 IS IS5889A patent/IS5889A/is unknown
- 2001-03-16 ZA ZA200102230A patent/ZA200102230B/en unknown
- 2001-03-29 NO NO20011615A patent/NO20011615L/no not_active Application Discontinuation
- 2001-04-25 BG BG105471A patent/BG105471A/xx unknown
2007
- 2007-11-28 US US11/946,217 patent/US20080119561A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1042436A1 (en)	2002-08-16
CA2343299C (en)	2008-04-01
YU23901A (sh)	2003-07-07
AP2001002112A0 (en)	2001-06-30
EP1117392B1 (de)	2004-02-25
NZ510500A (en)	2003-10-31
HUP0103648A2 (hu)	2003-08-28
CN1342072A (zh)	2002-03-27
DE69915084D1 (de)	2004-04-01
EP1117392A1 (de)	2001-07-25
ATE260100T1 (de)	2004-03-15
CA2343299A1 (en)	2000-04-06
EA007427B1 (ru)	2006-10-27
SI1117392T1 (en)	2004-06-30
EE200100199A (et)	2002-06-17
NO20011615D0 (no)	2001-03-29
PL346980A1 (en)	2002-03-11
PT1117392E (pt)	2004-07-30
CN1197565C (zh)	2005-04-20
BG105471A (bg)	2001-12-31
EA200100370A1 (ru)	2001-10-22
ZA200102230B (en)	2002-06-18
DK1117392T3 (da)	2004-06-14
ES2214872T3 (es)	2004-09-16
TR200100901T2 (tr)	2001-08-21
US20080119561A1 (en)	2008-05-22
WO2000018395A1 (en)	2000-04-06
IL141953A0 (en)	2002-03-10
AU768474B2 (en)	2003-12-11
HUP0103648A3 (en)	2003-10-28
IS5889A (is)	2001-03-14
HRP20010236A2 (en)	2002-04-30
AU4975099A (en)	2000-04-17
AP1708A (en)	2007-01-10
OA11787A (en)	2005-07-26
SK4122001A3 (en)	2002-06-04
JP2002525321A (ja)	2002-08-13
NO20011615L (no)	2001-04-24
CZ20011035A3 (cs)	2001-10-17
KR20010079955A (ko)	2001-08-22
BR9914098A (pt)	2001-07-31
DE69915084T2 (de)	2004-07-22
ID30255A (id)	2001-11-15
IL141953A (en)	2006-07-05

Publication	Publication Date	Title
US20080119561A1 (en)	2008-05-22	Methods for preventing or delaying catheter- based resvascularization
Cacciatore et al.	1991	Angina pectoris
CN101217952B (zh)	2014-03-12	用于预防心血管事件发病的组合物
US6180660B1 (en)	2001-01-30	Cholesterol-lowering therapy
US8343947B2 (en)	2013-01-01	Therapeutic treatment
RS50485B (sr)	2010-03-02	Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
EA002705B1 (ru)	2002-08-29	Комбинационная терапия, включающая в себя амлодипин и статиновое соединение
JP2024527023A (ja)	2024-07-19	Ｈｉｓ低応答者の治療
JP2002508320A (ja)	2002-03-19	スタチン−カルボキシアルキルエーテル配合物
Richartz et al.	2001	Reversibility of coronary endothelial vasomotor dysfunction in idiopathic dilated cardiomyopathy: acute effects of vitamin C
Schachter	1997	Calcium antagonists and atherosclerosis
Odoemene et al.	2017	Ureterolithiasis: management in an environment with limited facilities
US20060160896A1 (en)	2006-07-20	Therapeutic treatment
Kurata et al.	2001	Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
Chilton et al.	2001	The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease
Hirsch et al.	2001	Intermittent claudication
US20030191177A1 (en)	2003-10-09	Fomulation
NZ502874A (en)	2004-03-26	Antihyperlipidemic statin-lp(a) inhibitor combinations
MXPA01003290A (es)	2002-02-26	Metodo para prevenir o retardar la revascularizacion a base de cateteres
Andryskowski et al.	2008	Effect of calcium lactate supplementation on cholesterol concentration in patients with hyperlipidaemia and previous viral hepatitis: a preliminary report: cardiovascular topics
WO2012116997A1 (en)	2012-09-07	TREATMENT OF ARTERIAL AGEING BY HMG CoA REDUCTASE INHIBITOR
Hagerty	2012	Comparing Two Different Statins in a Delayed Pharmacological Treatment for Ischemic Stroke